For most people, 5001,500 mg/day is a sensible range
Publisher | Google Scholor Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, et al
During GLP-1 treatment , contact your GP if you experience: Severe or persistent abdominal pain , particularly if different in character from your usual IBS symptoms or if radiating to your back (which may indicate pancreatitisstop the medication and seek urgent medical attention) Significant worsening of diarrhoea or constipation that doesn't improve with standard measures Persistent nausea or vomiting affecting your ability to maintain adequate nutrition and hydration New symptoms such as rectal bleeding, unintentional weight loss (beyond expected therapeutic effect), or nocturnal symptoms waking you from sleep Difficulty distinguishing between IBS symptoms and medication side effects Sudden pain in the upper right abdomen, fever, or yellowing of the skin/eyes (possible gallbladder diseaseseek urgent medical attention) Red flag symptoms requiring urgent medical attention include: Severe, unremitting abdominal pain Rectal bleeding or black, tarry stools Unexplained weight loss Persistent vomiting with inability to keep fluids down Signs of dehydration Your GP may arrange appropriate investigations such as blood tests (full blood count, inflammatory markers, coeliac serology) or faecal calprotectin testing to distinguish IBS from inflammatory bowel disease where appropriate
AUC and peak concentration of active drug in the body
Best practice involves additional education in obesity medicineunderstanding the pathophysiology of weight regulation, contraindications for weight-loss drugs, monitoring protocols, and nutritional counseling basics
Our findings that dual GDF8/ActA blockade preserves muscle during GLP-1 RA-induced weight loss, thus increasing fat loss and associated metabolic benefits, has the potential to greatly amplify the benefits of GLP-1 RA treatment
